Previous 10 | Next 10 |
Intra-Cellular Therapies Inc. (ITCI) is expected to report $-0.59 for Q3 2023
2023-11-01 13:12:50 ET More on Intra-Cellular Therapies Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline Intra-Cellular Therapies, Inc. (ITCI) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Intra-Cellular Therapies Hi...
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor con...
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast ...
2023-10-16 08:30:08 ET PCTEL ( NASDAQ: PCTI ) +48% . Essa Pharma ( EPIX ) +32% . Almacenes Exito ( EXTO ) +32% . Ambrx Biopharma ( AMAM ) +32% Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX5...
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the 2023 Cantor Fitzgerald G...
NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the 2023 Psych...
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Morgan Stanley 21st...
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
2023-08-12 10:29:03 ET Summary Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed features in mood disorders. Q2 2023 earnings report showed substantial revenue growth driven by Capl...
News, Short Squeeze, Breakout and More Instantly...
Intra-Cellular Therapies Inc. Company Name:
ITCI Stock Symbol:
NASDAQ Market:
Intra-Cellular Therapies Inc. Website:
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development ...
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and ...